New drug aims to stop pouchitis before it starts
NCT ID NCT07486921
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug etrasimod can prevent pouchitis, a common inflammation of the internal pouch created after colon removal surgery. Researchers will give either etrasimod or a placebo to 40 high-risk patients for 48 weeks and track how many develop pouchitis. The goal is to see if this medication can stop the condition from occurring in the first place.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POUCHITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icahn School Of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sound waves vs. scope: a gentler way to spot pouch inflammation?
- Can a stool transplant calm an inflamed pouch?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?